MarkMZalupskiMD

Oncology • Ann Arbor, MI

Professor, Internal Medicine, University of Michigan Medical School

Join to view full profile

Dr. Zalupski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Zalupski's full profile

Already have an account?

Office
1500 East Medical Center Dr
B1 Floor Cancer Ctr Recp C
Ann Arbor, MI 48109
Phone+1 734-647-8902
Is this information wrong?

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 1986 - 1989
Wayne State University School of MedicineResidency, Internal Medicine, 1982 - 1986
Wayne State University School of MedicineClass of 1982

Certifications & Licensure

MI State Medical License 1985 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors Start of enrollment: 2000 Apr 01
Completed
Phase 2
Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site Start of enrollment: 2001 May 01
Terminated
Phase 2
Capecitabine and Radiation Therapy in Advanced Pancreatic Cancer Start of enrollment: 2001 Dec 01
Terminated
Not Applicable
Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine Start of enrollment: 2000 Mar 01
Terminated
Phase 2
Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma Start of enrollment: 2001 Feb 01
Completed
Phase 2
Radiation Therapy With Capecitabine in Rectal Cancer Start of enrollment: 2000 Oct 01
Terminated
Phase 2
Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer Start of enrollment: 2003 Mar 01
Completed
Phase 2
Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer Start of enrollment: 2003 Jun 01
Completed
Phase 2
Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer Start of enrollment: 2004 Jun 01
Completed
Phase 1, Phase 2
Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma Start of enrollment: 2004 Feb 01
Completed
Phase 1
Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer Start of enrollment: 2007 Apr 01
Completed
Phase 2
Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer Start of enrollment: 2006 Jun 01
Completed
Phase 1, Phase 2
Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer Start of enrollment: 2010 Jun 01
Completed
Phase 2
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Start of enrollment: 2011 Dec 12
Completed
Phase 1, Phase 2
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Start of enrollment: 2012 Feb 01
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2012 May 15
Active, not recruiting
Phase 2
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients Start of enrollment: 2011 Jun 01
Completed
Phase 2
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers Start of enrollment: 2011 Jul 01
Completed
Phase 2
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer Start of enrollment: 2012 Jul 01
Completed
Phase 1
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer Start of enrollment: 2014 May 01
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

Genomics driven precision oncology in advanced biliary tract cancer improves survival.
Chandan Kumar-Sinha, Pankaj Vats, Nguyen Tran, Dan R Robinson, Valerie Gunchick, Yi-Mi Wu, Xuhong Cao, Yu Ning, Rui Wang, Erica Rabban, Janice Bell, Sunita Shankar, Ra...> ;Neoplasia. 2023 Aug 1
4 citations
Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04).
Arathi Mohan, Kent A Griffith, Fulei Wuchu, David B Zhen, Chandan Kumar-Sinha, Oxana Crysler, David Hsiehchen, Thomas Enzler, Dominique Dippman, Valerie Gunchick, Abhi...> ;Clinical Cancer Research. 2023 Jul 5
2 citations
Survival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy.
Valerie Gunchick, Rachel L McDevitt, Elizabeth Choi, Katherine Winslow, Mark M Zalupski, Vaibhav Sahai> ;The Oncologist. 2023 Jun 2
Reply to "Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?"
Vaibhav Sahai, Mark M Zalupski> ;Cancer. 2023 Apr 1
33 citations
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).
Pamela L Kunz, Noah T Graham, Paul J Catalano, Halla S Nimeiri, George A Fisher, Teri A Longacre, Carlos J Suarez, Brock A Martin, James C Yao, Matthew H Kulke, Andrew...> ;Journal of Clinical Oncology. 2023 Mar 1
19 citations
A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01.
Vaibhav Sahai, Kent A Griffith, Muhammad S Beg, Walid L Shaib, Devalingam Mahalingam, David B Zhen, Dustin A Deming, Mark M Zalupski> ;Cancer. 2022 Oct 1
Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials.
Matthew Ledenko, Samuel O Antwi, Shiho Arima, Julia Driscoll, Junji Furuse, Heinz-Josef Klümpen, Finn Ole Larsen, David K Lau, Annett Maderer, Alice Markussen, Markus ...> ;Frontiers in Oncology. 2022 Jan 1
1 citations
Motor "freezing" with oxaliplatin.
Monica A. Patel, Rachel L McDevitt, Will Sassack, Mark M. Zalupski> ;Journal of Oncology Pharmacy Practice. 2021 Mar 26
78 citations
Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
Erin F. Cobain, Yi-Mi Wu, Pankaj Vats, Rashmi Chugh, Francis P. Worden, David Smith, Scott M. Schuetze, Mark M. Zalupski, Vaibhav Sahai, Ajjai Alva, Anne F. Schott, Me...> ;JAMA Oncology. 2021 Apr 1
11 citations
Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.
Francesco Giovinazzo, Fiammetta Soggiu, Jin-Young Jang, Eva Versteijne, Geertjan van Tienhoven, Casper H.J. van Eijck, Youngmin Han, Seong Ho Choi, Chang Moo Kang, Mar...> ;Frontiers in Oncology. 2020 Aug 11
201 citations
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation
Eileen M. O'Reilly, Jonathan W. Lee, Mark M. Zalupski, Marinela Capanu, Jennifer Park, Talia Golan, Esther Tahover, Maeve A. Lowery, Joanne F. Chou, Vaibhav Sahai, Rob...> ;Journal of Clinical Oncology. 2020 Jan 24
24 citations
Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pa...
Nguyen H. Tran, Vaibhav Sahai, Kent A. Griffith, Hari Nathan, Ravi K. Kaza, Kyle C. Cuneo, Jiaqi Shi, Edward J. Kim, Christopher J. Sonnenday, Clifford S. Cho, Theodor...> ;International Journal of Radiation Oncology, Biology, Physics. 2020 Jan 1
7 citations
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype...
Smita S. Joshi, Daniel V.T. Catenacci, Theodore Karrison, Jaclyn D Peterson, Mark M. Zalupski, Amikar Sehdev, James L. Wade, Ahad Ali Sadiq, Vincent J. Picozzi, Andrea...> ;Clinical Cancer Research. 2020 Jan 1
111 citations
Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer.
Kyle C. Cuneo, Meredith A. Morgan, Vaibhav Sahai, Matthew J. Schipper, Leslie A. Parsels, Joshua D. Parsels, Theresa Devasia, Mahmoud Al-Hawaray, Clifford S. Cho, Hari...> ;Journal of Clinical Oncology. 2019 Aug 9
3 citations
Irinotecan-associated dysarthria: A single institution case series with management implications in patients with gastrointestinal malignancies.
David B Zhen, Rachel L McDevitt, Mark M. Zalupski, Vaibhav Sahai> ;Journal of Oncology Pharmacy Practice. 2019 Jun 1
73 citations
Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Vaibhav Sahai, Paul J. Catalano, Mark M. Zalupski, Sam J. Lubner, Mark R. Menge, Halla Sayed Nimeiri, Hidayatullah G. Munshi, Al B. Benson, Peter J. O'Dwyer> ;JAMA Oncology. 2018 Dec 1
13 citations
Prognostic Value of c-MET Expression in Patients With Pancreatic Cancer Receiving Adjuvant and Neoadjuvant Chemoradiation Therapy.
Kyle C. Cuneo, Meredith A. Morgan, Kent A. Griffith, Peter G. Hawkins, Joel K. Greenson, Edgar Ben-Josef, Theodore S. Lawrence, Mark M. Zalupski> ;International Journal of Radiation Oncology, Biology, Physics. 2018 Feb 1
294 citations
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Duct...
Sunil R. Hingorani, Lei Zheng, Andrea J. Bullock, Tara Elisabeth Seery, William P. Harris, Darren Sigal, Fadi Braiteh, Paul S. Ritch, Mark M. Zalupski, Nathan Bahary, ...> ;Journal of Clinical Oncology. 2017 Dec 12
545 citations
Integrative clinical genomics of metastatic cancer
Dan R. Robinson, Yi-Mi Wu, Robert J. Lonigro, Pankaj Vats, Erin F. Cobain, Jessica Everett, Xuhong Cao, Erica Rabban, Chandan Kumar-Sinha, Victoria M. Raymond, Scott M...> ;Nature. 2017 Aug 2
69 citations
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
Johanna C. Bendell, Milind Javle, Tanios Bekaii-Saab, Richard S. Finn, Zev A. Wainberg, Daniel A. Laheru, Colin D. Weekes, Benjamin R. Tan, Gazala Khan, Mark M. Zalups...> ;British Journal of Cancer. 2017 Feb 28
3 citations
Definitive Chemoradiation With Full-dose Gemcitabine for Unresectable Pancreatic Cancer: Efficacy of Involved-Field Radiotherapy.
Jessica Zhou, Charles X. Fang, Jincheng Shen, Matthew J. Schipper, Mark M. Zalupski, Rebecca M. Minter, Diane M. Simeone, Deanna Hart, Taylor Eagle, Grace W. Kimmel, J...> ;American Journal of Clinical Oncology. 2017 Jan 1
11 citations
Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of...
Shubham Pant, Ludmila Katherine Martin, Susan Geyer, Lai Wei, Katherine Van Loon, Nili Sommovilla, Mark M. Zalupski, Renuka Iyer, David R. Fogelman, Andrew H. Ko, Tani...> ;American Journal of Clinical Oncology. 2016 Dec 1
2 citations
SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy.
Elizabeth J. Davis, Lili Zhao, David R. Lucas, Scott M. Schuetze, Laurence H. Baker, Mark M. Zalupski, Dafydd G. Thomas, Rashmi Chugh> ;BMC Cancer. 2016 Aug 20
24 citations
A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer.
David Bing Zhen, Kent A. Griffith, Joshua M. Ruch, Kevin Camphausen, Jason E. Savage, Edward J. Kim, Vaibhav Sahai, Diane M. Simeone, Mark M. Zalupski> ;Investigational New Drugs. 2016 Jul 21
6 citations
A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve Pancrea...
Steven J. Cohen, Mark M. Zalupski, Paul Conkling, Francis W. Nugent, Wen Wee Ma, Manuel Modiano, Rolan Pascual, Fa-Chyi Lee, Lucas Wong, Evan M. Hersh> ;American Journal of Clinical Oncology. 2015 Dec 24
Join now to see all

Journal Articles

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors
Erin F Cobain, Francis Worden, Scott M Schuetze, Mark M Zalupski, Vaibhav Sahai, Ajjai Alva, Anne F Schott, Moshe Talpaz, JAMA Oncology

Press Mentions

Pancreatic Cancer Survivor’s Advice: Don’t Give up on Finding AnswersOctober 30th, 2020
Relocating for Pancreatic Cancer Treatment and a Clinical TrialMay 23rd, 2019